Sebahat Ocak1, Fabrice Duplaquet2, Jacques Jamart3, Lionel Pirard2, Birgit Weynand4, Monique Delos4, Philippe Eucher5, Benoît Rondelet5, Michael Dupont6, Luc Delaunois2, Yves Sibille2, Caroline Dahlqvist2. 1. Division of Pulmonology, Centre Hospitalier Universitaire Dinant-Godinne, Université Catholique de Louvain Namur, Avenue G. Thérasse, 1, B5530 Yvoir, Belgium. Electronic address: sebahat.ocak@uclouvain.be. 2. Division of Pulmonology, Centre Hospitalier Universitaire Dinant-Godinne, Université Catholique de Louvain Namur, Avenue G. Thérasse, 1, B5530 Yvoir, Belgium. 3. Scientific Support Unit, Centre Hospitalier Universitaire Dinant-Godinne, Université Catholique de Louvain Namur, Avenue G. Thérasse, 1, B5530 Yvoir, Belgium. 4. Department of Pathology, Centre Hospitalier Universitaire Dinant-Godinne, Université Catholique de Louvain Namur, Avenue G. Thérasse, 1, B5530 Yvoir, Belgium. 5. Division of Cardio-Vascular and Thoracic Surgery, Centre Hospitalier Universitaire Dinant-Godinne, Université Catholique de Louvain Namur, Avenue G. Thérasse, 1, B5530 Yvoir, Belgium. 6. Department of Radiology, Centre Hospitalier Universitaire Dinant-Godinne, Université Catholique de Louvain Namur, Avenue G. Thérasse, 1, B5530 Yvoir, Belgium.
Abstract
PURPOSE: To compare the diagnostic accuracy and safety of a 14-gauge core needle versus a 22-gauge fine needle in the evaluation of thoracic lesions by CT-guided percutaneous transthoracic needle biopsy (TTNB). MATERIALS AND METHODS: Medical charts of all patients who underwent CT-guided percutaneous transthoracic core-needle biopsies (CNBs) with a 14-gauge Spirotome device (99 patients, 102 procedures) and fine-needle biopsies (FNBs) with a 22-gauge Rotex needle (92 patients, 102 procedures) between 2007 and 2013 at a single academic institution were retrospectively reviewed. Variables that could influence diagnostic accuracy and safety were collected. RESULTS: The overall and cancer-specific diagnostic accuracy rates were 90% and 94%, respectively, with CNB, versus 82% and 89% with FNB. Precise cancer type/subtype was provided by 97% of CNBs versus 65% of FNBs (P < .001). In patients with lung cancer considered for targeted therapy, biomarker analyses were feasible in 80% of CNBs versus 0% of FNBs (P < .001). The rate of pneumothorax was significantly higher with CNB versus FNB (31% vs 19%; P = .004), but chest tube insertion rates were similar (10% vs 11%, respectively). Major bleeding complications occurred in 1% of CNBs versus 2% of FNBs and were associated with one death in the CNB group. CONCLUSIONS: Percutaneous transthoracic CNB with a 14-gauge Spirotome needle provided better characterization of cancer lesions and allowed biomarker analyses without a significant increase in major procedural complications.
PURPOSE: To compare the diagnostic accuracy and safety of a 14-gauge core needle versus a 22-gauge fine needle in the evaluation of thoracic lesions by CT-guided percutaneous transthoracic needle biopsy (TTNB). MATERIALS AND METHODS: Medical charts of all patients who underwent CT-guided percutaneous transthoracic core-needle biopsies (CNBs) with a 14-gauge Spirotome device (99 patients, 102 procedures) and fine-needle biopsies (FNBs) with a 22-gauge Rotex needle (92 patients, 102 procedures) between 2007 and 2013 at a single academic institution were retrospectively reviewed. Variables that could influence diagnostic accuracy and safety were collected. RESULTS: The overall and cancer-specific diagnostic accuracy rates were 90% and 94%, respectively, with CNB, versus 82% and 89% with FNB. Precise cancer type/subtype was provided by 97% of CNBs versus 65% of FNBs (P < .001). In patients with lung cancer considered for targeted therapy, biomarker analyses were feasible in 80% of CNBs versus 0% of FNBs (P < .001). The rate of pneumothorax was significantly higher with CNB versus FNB (31% vs 19%; P = .004), but chest tube insertion rates were similar (10% vs 11%, respectively). Major bleeding complications occurred in 1% of CNBs versus 2% of FNBs and were associated with one death in the CNB group. CONCLUSIONS: Percutaneous transthoracic CNB with a 14-gauge Spirotome needle provided better characterization of cancer lesions and allowed biomarker analyses without a significant increase in major procedural complications.
Authors: Leslie J Kohman; Lin Gu; Nasser Altorki; Ernest Scalzetti; Linda J Veit; Jason M Wallen; Xiaofei Wang Journal: J Thorac Cardiovasc Surg Date: 2017-02-07 Impact factor: 5.209
Authors: Sharath K Bhagavatula; Kunj Upadhyaya; Brendyn J Miller; Patrick Bursch; Alex Lammers; Michael J Cima; Stuart G Silverman; Oliver Jonas Journal: Med Phys Date: 2019-09-26 Impact factor: 4.071